Prestige Consumer Healthcare Inc. · NYSE:PBH

Prestige Consumer Healthcare — Prestige Brands Holdings — Q1 FY2014 Earnings Presentation

30 slides from Prestige Consumer Healthcare's earnings presentation, Aug 1, 2013

  1. Slide 1: Review of First Quarter F'14 Results

    P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 4 R e s u l t s 1 Review of First Quarter F’14 Results Matt Mannelly, CEO & President Ron Lombardi, CFO August 1, 2013 Exhibit 99.2

  2. Slide 2: Safe Harbor Disclosure

    P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 4 R e s u l t s 2 This presentation contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements about the Company’s growth strategies, investments in advertising

  3. Slide 3: Agenda for Today's Discussion

    P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 4 R e s u l t s 3 1. Q1 FY2014: Performance Highlights 2. Acquisition 3. Q1 FY2014: Financial Overview 4. FY2014 Outlook and The Road Ahead Agenda for Today’s Discussion

  4. Slide 4: Our Corporate Mission

    P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 4 R e s u l t s 4 Our Corporate Mission To be the Best Mid-Sized, Public Company in the Consumer Health Care Market The following principles guide us in this endeavor:  deliver outstanding shareholder value through superior growth in sales,

  5. Slide 5: Q1 FY2014: Performance Highlights

    P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 4 R e s u l t s 5 Q1 FY2014: Performance Highlights

  6. Slide 6: Q1: Executing Against Our Proven Formula for Continued E.P.S. Growth

    P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 4 R e s u l t s 6 Q1: Executing Against Our Proven Formula for Continued E.P.S. Growth Note: (1) Management estimate for weighted average growth rate for Prestige Brands’ Core OTC categories. + + >$125 MM per year Predictable E.P.S. Impact 1-

  7. Slide 7: First Quarter Highlights: Delivering Against Stated Strategy

    P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 4 R e s u l t s 7 First Quarter Highlights: Delivering Against Stated Strategy  Solid financial performance: +14.3% Adjusted E.P.S. growth − Q1 consolidated net revenue of $143.0 million, down (1.9%) versus prior year excluding divested Phaz

  8. Slide 8: Performance of Core OTC Portfolio

    P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 4 R e s u l t s 8 Performance of Core OTC Portfolio Source: Latest 12-week IRI multi-outlet retail dollar sales growth for relevant quarter. Note: Data reflects retail dollar sales percentage growth versus prior period. (1) Excludes expected

  9. Slide 9: Brand Building: Continued New Product Innovation

    P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 4 R e s u l t s 9 Brand Building: Continued New Product Innovation

  10. Slide 10: Introducing New Headache Relief Shots

    P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 4 R e s u l t s 1 0 Introducing New Headache Relief Shots  Fast Liquid Action  Long Lasting Relief  Convenience  Great Tasting Flavors

  11. Slide 11: Introducing New Cherry

    P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 4 R e s u l t s 1 1 Introducing New Cherry  Safe Fast Pain Relief in a Great Tasting Cherry Flavor  Convenient Stick Pack Delivery System  Powders are Preferred in the South

  12. Slide 12: Introducing Fruity Bites

    P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 4 R e s u l t s 1 2 Introducing Fruity Bites: A Great-Tasting New Fiber Gummy to Promote G.I. Health Supported by print advertising in major magazines

  13. Slide 13: Vanessa Williams Campaign Reaches A New Audience

    P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 4 R e s u l t s 1 3 Vanessa Williams Campaign Reaches A New Audience  Television Advertising Campaign conveys the “healthy eyes” message  Strong Digital Presence  Social Media Component  Extensive PR Effort Reaches Targeted Media & Consum

  14. Slide 14: Acquisition

    P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 4 R e s u l t s 1 4 Acquisition

  15. Slide 15: The Care Pharmaceuticals Acquisition

    P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 4 R e s u l t s 1 5 The Care Pharmaceuticals Acquisition  Overview: Australian based marketer and distributor of “heritage” OTC brands for adults and children  Headquarters: Sydney, Australia  Employees: 35 employees including 17-person sa

  16. Slide 16: A Portfolio of Leading Brands in Niche Categories

    P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 4 R e s u l t s 1 6 A Portfolio of Leading Brands in Niche Categories P edi at ric s W ome n 's He alt h Brand Market Position #1 #3 #1 #2 #1 #1 #5 #2 Respiratory Anorectal Laxatives Iron Supplements Eye Wipes Ovulation Testing Cough Cold Fem

  17. Slide 17: Strategic Rationale

    P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 4 R e s u l t s 1 7 Strategic Rationale  Establishes local presence in Australia and New Zealand  Leverages and strengthens competencies in cough-cold, eye and ear care, and pediatrics  Allows for the consolidation of Murine into Care Phar

  18. Slide 18: The Road Ahead: Where Are We Going?

    P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 4 R e s u l t s 1 8 The Road Ahead: Where Are We Going?  Profitable “stand-alone” OTC business  Closely aligned business model and culture  Management team with proven brand building and M&A capabilities  Near-term revenue synergy opportu

  19. Slide 19: Care Represents Another Step in the Expansion of Prestige's International Business

    P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 4 R e s u l t s 1 9 Care Represents Another Step in the Expansion of Prestige’s International Business Pre-GSK Post-GSK Post-Care U.S. International U.S. International U.S. International  Distributor model  Predominantly established markets

  20. Slide 20: Prestige has a Proven Ability To Source M&A Opportunities

    P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 4 R e s u l t s 2 0 Prestige has a Proven Ability To Source M&A Opportunities…

  21. Slide 21: And Execute in Diverse Situations

    P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 4 R e s u l t s 2 1 …And Execute in Diverse Situations Key Brands # of Brands: 5 1 17 11 Source: Private Equity Large U.S. Pharma Large U.K. Pharma Private Aus. OTC Type of Transaction: Going Concern Brand Sale Carve-Out Going Concern Process

  22. Slide 22: Q1 FY2014: Financial Overview

    P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 4 R e s u l t s 2 2 Q1 FY2014: Financial Overview

  23. Slide 23: Summary Financial Performance

    P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 4 R e s u l t s 2 3 Summary Financial Performance Dollar values in millions, except per share data Notes: (1) Reported net revenue for Q1 FY’13 was $147.0 million. Adjusted net revenue for Q1 FY’13 was $147.4 million and excludes transition r

  24. Slide 24: Q1 Consolidated Financial Summary

    P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 4 R e s u l t s 2 4  Adjusted Net Revenue declined ($2.7) million, or (1.9%), excluding results in prior year quarter from the divested Phazyme brand – Excluding the Pediatrics portfolio and Beano, core OTC revenue growth of 4.5% over the pr

  25. Slide 25: Net Income and E.P.S. Reconciliation

    P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 4 R e s u l t s 2 5 Net Income and E.P.S. Reconciliation Dollar values in millions, except per share data Note: These Non-GAAP financial measures are reconciled to their reported GAAP amounts in our Earnings Release in the “About Non-GAAP Fin

  26. Slide 26: Debt Profile & Financial Compliance

    P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 4 R e s u l t s 2 6 Debt Profile & Financial Compliance:  Total Net Debt at 6/30/13 of $941 million comprised of: – Cash on hand of $19.3 million – $445 million of term loan – $500 million of bonds – $15 million of revolver  Leverage ratio(

  27. Slide 27: FY2014 Outlook and Road Ahead

    P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 4 R e s u l t s 2 7 FY2014 Outlook and Road Ahead

  28. Slide 28: FY Focus

    P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 4 R e s u l t s 2 8 FY 14 Focus  Stay the course in a transitional marketplace − Continue brand building and investing in Core OTC portfolio • New ad campaigns for Goody’s, Gaviscon, PediaCare, and Beano beginning in Q2 • Launch PediaCare Si

  29. Slide 29: Our confidence for Long-Term E.P.S. Guidance

    P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 4 R e s u l t s 2 9 Our confidence for Long-Term E.P.S. Guidance +

  30. Slide 30: R e s u l t s

    P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 4 R e s u l t s 3 0

Prestige Brands Holdings — Q1 FY2014 Earnings Presentation on 6ix